Citations (4)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Zhaonan Li & Xinwei Han. (2020) Re: Chen S, Shi M, Shen L, et al. Microwave ablation versus sorafenib for intermediate-stage hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis. Int J hyperthermia 2020. International Journal of Hyperthermia 37:1, pages 1312-1312.
Read now
Read now
Articles from other publishers (3)
Jason K. Wong, Howard J. Lim, Vincent C. Tam, Kelly W. Burak, Laura A. Dawson, Prosanto Chaudhury, Robert J. Abraham, Brandon M. Meyers, Gonzalo Sapisochin, David Valenti, Setareh Samimi, Ravi Ramjeesingh, Amol Mujoomdar, Ilidio Martins, Elijah Dixon, Maja Segedi & David M. Liu. (2023) Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada. Cancer Treatment Reviews 115, pages 102526.
Crossref
Crossref
Shen Zhang, Wan-Sheng Wang, Bin-Yan Zhong & Cai-Fang Ni. (2022) Subsequent Treatment after Transarterial Chemoembolization Failure/Refractoriness: A Review Based on Published Evidence. Journal of Clinical and Translational Hepatology 10:4, pages 740-747.
Crossref
Crossref
Shen Zhang, Bin-Yan Zhong, Lei Zhang, Wan-Sheng Wang & Cai-Fang Ni. (2022) Transarterial chemoembolization failure/refractoriness: A scientific concept or pseudo-proposition. World Journal of Gastrointestinal Surgery 14:6, pages 528-537.
Crossref
Crossref